The Government Knows Something About CBG That We Don’t
Cannabigerol (CBG) is a core ingredient in our PURPOSE formula because it is a powerful cannabinoid. Much of our decision to use this ingredient was because of the anecdotal evidence supporting its use rather than the scientific. Of course, there is scientific information, but like many new cannabinoids, there hasn’t been enough time or money to fully fund long-term human trials with CBG.
What we know intuitively and from experience we have a hard time explaining to the wider world. But sometimes the government lets us in on a secret or two about the future of a particular compound. With the case of CBG, a patent proposal invitation from the National Center for Complementary and Integrative Health (NCCIH) shows us a potential use case for pain management or “analgesic properties” (along with other cannabinoids).
Nothing is confirmed yet. We don’t know for sure what evidence the government has uncovered, but we do know that the government organizations are interested in funding research that may potentially lead to discoveries with this use case. For those who are trying to parse together some quantifiable data about CBG and other new cannabinoids, the government may consistently give us clues.
Using a more integrative approach, CBG has responded well with our participants in applied kinesiology (muscle testing).
Energetic meridians increased and many of the subjects who took PURPOSE acknowledged increased euphoria or mood enhancing effects. This showcases BioEnhanced CBG, a highly absorbable form, but also includes adaptogens.
Before we tested with our friends and family, we hadn’t seen or heard that there may be pain relieving properties. On our next batch of testing, the government has made it clear that surveys should check in about pain management. At least some of our tax money is going to good use…